Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 0.48% | 53.97 | 0.9% | $1408.01m | |
| JNJ | Johnson & Johnson | -0.05% | 179.54 | 0.7% | $1296.44m | |
| BMY | Bristol-Myers Squibb Co. | 0.45% | 77.59 | 1.0% | $1212.16m | |
| MRK | Merck & Co., Inc. | -1.53% | 92.32 | 0.7% | $1167.02m | |
| ABBV | AbbVie, Inc. | -0.92% | 150.56 | 1.9% | $1100.30m | |
| LLY | Eli Lilly & Co. | 2.11% | 313.48 | 1.1% | $967.28m | |
| BHVN | Biohaven Pharmaceutical Holding Co. Ltd. | -0.29% | 142.98 | 0.0% | $491.89m | |
| AZN | AstraZeneca Plc | -0.17% | 66.70 | 1.0% | $491.50m | |
| NVS | Novartis AG | 0.01% | 91.26 | 0.2% | $259.85m | |
| GSK | GlaxoSmithKline Plc | -1.23% | 44.42 | 0.2% | $257.59m | |
| VERU | Veru, Inc. | 2.18% | 12.64 | 0.0% | $253.71m | |
| HZNP | Horizon Therapeutics Plc | 2.45% | 90.59 | 5.4% | $196.03m | |
| SGEN | Seagen Inc. | 1.46% | 138.46 | 5.7% | $185.67m | |
| NVO | Novo Nordisk A/S | 1.30% | 106.62 | 0.1% | $182.89m | |
| VTRS | Viatris, Inc. | 1.44% | 12.01 | 0.0% | $165.27m |
Company Profile
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.